The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population
Author:
Publisher
Elsevier BV
Subject
Geriatrics and Gerontology,Oncology
Reference39 articles.
1. FDA approval of nivolumab for the first-line treatment of patients with BRAFV600 wild-type unresectable or metastatic melanoma;Beaver;Clin Cancer Res,2017
2. US FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab;Hazarika;Clin Cancer Res,2017
3. PS01.53: first-line atezolizumab plus Cancer immunotherapies in the elderly 577 chemotherapy in chemotherapy-naive patients with advanced NSCLC: a phase III clinical program: topic: medical oncology;Jotte;J Thorac Oncol,2016
4. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study;Hellmann;Lancet Oncol,2017
5. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015
Cited by 53 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Age-related outcomes in MSI/dMMR gastrointestinal cancers treated by immune checkpoint inhibitors and toxicity’s impact on efficacy: an immunoMSI cohort study;ESMO Gastrointestinal Oncology;2024-06
2. Incidence and risk factors of immune‐related adverse events induced by immune checkpoint inhibitors among older adults with non‐small cell lung cancer;Cancer Medicine;2024-01
3. Immunotherapy in Older Patients with Cancer: A Narrative Review;International Journal of General Medicine;2024-01
4. Key Considerations for the Treatment of Advanced Breast Cancer in Older Adults: An Expert Consensus of the Canadian Treatment Landscape;Current Oncology;2023-12-26
5. Predictive Factors in Metastatic Melanoma Treated with Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective;Cancers;2023-12-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3